Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

Mirjam K de Vries, Izhar C van Eijk, Irene E van der Horst-Bruinsma, Mike J L Peters, Michael T Nurmohamed, Ben A C Dijkmans, Bouke P C Hazenberg, Gerrit J Wolbink
{"title":"Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.","authors":"Mirjam K de Vries,&nbsp;Izhar C van Eijk,&nbsp;Irene E van der Horst-Bruinsma,&nbsp;Mike J L Peters,&nbsp;Michael T Nurmohamed,&nbsp;Ben A C Dijkmans,&nbsp;Bouke P C Hazenberg,&nbsp;Gerrit J Wolbink","doi":"10.1002/art.24838","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To study the usefulness of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA) for response prediction and monitoring of anti-tumor necrosis factor (anti-TNF) treatment in ankylosing spondylitis (AS) patients.</p><p><strong>Methods: </strong>Patients were included consecutively before starting etanercept or infliximab treatment. ASsessment in Ankylosing Spondylitis (ASAS) response, defined as a 50% improvement or an absolute improvement of 2 points of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; 0-10 scale), was assessed at 3 months. Inflammatory markers and the BASDAI were collected at baseline and 1 and 3 months. Longitudinal data analysis was performed to compare associations between inflammatory markers and the BASDAI over time by calculating standardized betas. Predictive values of baseline levels of inflammatory markers for ASAS response were calculated.</p><p><strong>Results: </strong>In total, 155 patients were included, of whom, after 3 months of treatment, 70% in the etanercept cohort and 71% in the infliximab cohort responded. All markers, notably SAA, decreased significantly (P < 0.0001). Standardized betas were 0.49 for ESR, 0.43 for CRP, and 0.39 for SAA. Normal baseline levels of CRP and SAA were significantly associated with nonresponse. A combination of elevated CRP and SAA levels at baseline revealed the highest predictive value (81%) for ASAS response.</p><p><strong>Conclusion: </strong>ESR, CRP, and SAA were significantly associated with the BASDAI over 3 months, and the association with ESR was the strongest. Elevated baseline CRP and SAA levels revealed the highest predictive value for response. Together, this study demonstrates that inflammatory markers, and notably CRP and SAA, may facilitate patient selection and monitoring of efficacy of anti-TNF treatment in AS, and could be added to response criteria.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24838","citationCount":"121","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis and rheumatism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/art.24838","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 121

Abstract

Objective: To study the usefulness of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA) for response prediction and monitoring of anti-tumor necrosis factor (anti-TNF) treatment in ankylosing spondylitis (AS) patients.

Methods: Patients were included consecutively before starting etanercept or infliximab treatment. ASsessment in Ankylosing Spondylitis (ASAS) response, defined as a 50% improvement or an absolute improvement of 2 points of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; 0-10 scale), was assessed at 3 months. Inflammatory markers and the BASDAI were collected at baseline and 1 and 3 months. Longitudinal data analysis was performed to compare associations between inflammatory markers and the BASDAI over time by calculating standardized betas. Predictive values of baseline levels of inflammatory markers for ASAS response were calculated.

Results: In total, 155 patients were included, of whom, after 3 months of treatment, 70% in the etanercept cohort and 71% in the infliximab cohort responded. All markers, notably SAA, decreased significantly (P < 0.0001). Standardized betas were 0.49 for ESR, 0.43 for CRP, and 0.39 for SAA. Normal baseline levels of CRP and SAA were significantly associated with nonresponse. A combination of elevated CRP and SAA levels at baseline revealed the highest predictive value (81%) for ASAS response.

Conclusion: ESR, CRP, and SAA were significantly associated with the BASDAI over 3 months, and the association with ESR was the strongest. Elevated baseline CRP and SAA levels revealed the highest predictive value for response. Together, this study demonstrates that inflammatory markers, and notably CRP and SAA, may facilitate patient selection and monitoring of efficacy of anti-TNF treatment in AS, and could be added to response criteria.

强直性脊柱炎患者选择及抗肿瘤坏死因子治疗监测的红细胞沉降率、c反应蛋白水平和血清淀粉样蛋白。
目的:探讨血沉(ESR)、c反应蛋白(CRP)和血清淀粉样蛋白A (SAA)在强直性脊柱炎(AS)患者抗肿瘤坏死因子(anti-TNF)治疗疗效预测和监测中的应用价值。方法:在开始依那西普或英夫利昔单抗治疗前,连续纳入患者。强直性脊柱炎(ASAS)反应评估,定义为巴斯强直性脊柱炎疾病活动指数(BASDAI;0-10分),3个月时进行评估。在基线、1个月和3个月收集炎症标志物和BASDAI。通过计算标准化β,进行纵向数据分析,比较炎症标志物与BASDAI之间随时间的相关性。计算炎症标志物基线水平对ASAS反应的预测值。结果:共纳入155例患者,其中,在治疗3个月后,依那西普组70%有应答,英夫利昔单抗组71%有应答。所有指标,尤其是SAA均显著降低(P < 0.0001)。ESR的标准化β为0.49,CRP为0.43,SAA为0.39。正常的CRP和SAA基线水平与无反应显著相关。基线时CRP和SAA水平升高的组合显示asa反应的最高预测值(81%)。结论:ESR、CRP、SAA与3个月BASDAI有显著相关性,其中以ESR相关性最强。升高的基线CRP和SAA水平显示了反应的最高预测值。总之,本研究表明炎症标志物,尤其是CRP和SAA,可能有助于AS患者选择和监测抗tnf治疗的疗效,并可添加到反应标准中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Arthritis and rheumatism
Arthritis and rheumatism 医学-风湿病学
自引率
0.00%
发文量
0
审稿时长
1 months
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信